MCAS

Testing for MCAS When IBS Treatment Is Not Working

April 25, 202611 min readBy GLP1Gut Team
MCAS testingIBS treatment failureserum tryptaseN-methylhistamineprostaglandin D2

📋TL;DR: When IBS treatments fail and non-GI symptoms are present, MCAS testing should be considered. Key tests include serum tryptase drawn during a symptomatic episode, 24-hour urinary N-methylhistamine, and prostaglandin D2 metabolites. An H1/H2 antihistamine trial can provide diagnostic and therapeutic information. Allergists and immunologists experienced in mast cell disorders are the appropriate specialists for evaluation and ongoing management.

What We Know

  • Serum tryptase is the most widely accepted biomarker for mast cell activation, with a diagnostic threshold of baseline plus 20% plus 2 ng/mL during a symptomatic episode (Valent et al. 2012).
  • 24-hour urinary N-methylhistamine and prostaglandin D2 metabolites (11-beta-PGF2 alpha) can capture mast cell mediator release that serum tryptase misses (Akin 2017).
  • H1/H2 antihistamine combination therapy (cetirizine plus famotidine) is first-line treatment for MCAS and symptom response supports the diagnosis (Molderings et al. 2011).
  • Tryptase has a short half-life (approximately 2 hours), making timing of blood draws critical for capturing elevation during episodes (Schwartz 2006).
  • Cromolyn sodium (oral formulation) stabilizes mast cells in the GI tract and has demonstrated efficacy for GI-predominant MCAS symptoms (Klooker et al. 2010).

What We Don't Know

  • What percentage of IBS non-responders would test positive for MCAS if systematically evaluated with mast cell mediator panels.
  • Whether serum tryptase, urinary histamine metabolites, or urinary prostaglandin metabolites has the best sensitivity for GI-predominant MCAS.
  • The optimal duration and dosing of an H1/H2 antihistamine trial for diagnostic purposes in patients with GI-predominant symptoms.
  • How to reliably time laboratory testing to capture episodic mast cell mediator elevations in patients with unpredictable flare patterns.
  • Whether emerging biomarkers (chromogranin A, heparin, carboxypeptidase A3) will improve diagnostic sensitivity for MCAS.

You have followed the low-FODMAP diet, tried antispasmodics, and possibly cycled through fiber supplements and gut-brain modulators. Your IBS treatments have not produced lasting improvement, and you also have symptoms outside the GI tract: flushing, hives, brain fog, or a racing heart that your gastroenterologist has not explained. At this point, mast cell activation syndrome should be on the differential. MCAS testing is not part of standard gastroenterology workups, so getting evaluated requires knowing which tests to ask for, when to get them done, and which specialist to see. This guide covers the practical steps.

When should you consider MCAS testing?

MCAS testing becomes a reasonable next step under specific clinical circumstances. Consider pursuing evaluation if you have been diagnosed with IBS but standard treatments (dietary modification, antispasmodics, gut-brain modulators) have not produced adequate symptom control after at least 3-6 months of consistent effort. The case for MCAS testing strengthens further if you have GI symptoms that fluctuate in severity and appear to be triggered by histamine-rich foods (aged cheese, wine, fermented foods, cured meats), if you experience non-GI symptoms such as facial flushing, hives, dermatographism, brain fog, or tachycardia that occur alongside or independently of GI flares, if you have been diagnosed with or evaluated for hypermobile Ehlers-Danlos syndrome or POTS, or if you react to environmental triggers like heat, cold, stress, fragrances, or physical pressure in ways that seem disproportionate.

No single symptom is diagnostic, but the pattern matters. MCAS is a multi-system condition, and the more body systems involved, the stronger the clinical suspicion should be.

Serum tryptase: the primary blood test

Serum tryptase is the most widely accepted laboratory marker for mast cell activation. Tryptase is a protease released when mast cells degranulate. In MCAS, tryptase levels rise during symptomatic episodes and return to baseline between episodes. The diagnostic criterion established by the Valent consensus is an acute tryptase level that exceeds 20% above the patient's personal baseline plus 2 ng/mL. For example, if your baseline tryptase is 5 ng/mL, a level above 8 ng/mL during a flare (5 x 1.2 + 2 = 8) would meet the criterion.

The critical challenge with tryptase testing is timing. Tryptase has a half-life of approximately 2 hours, so blood must be drawn during or within 1-4 hours of a symptomatic episode. A tryptase drawn during a routine office visit when you are feeling fine is almost useless for MCAS diagnosis because it only captures the baseline. This is one of the main reasons MCAS gets missed: patients are tested at the wrong time, the result is normal, and the diagnosis is dismissed.

â„šī¸To maximize the diagnostic value of serum tryptase testing, ask your doctor for a standing order that allows you to go directly to a lab for a blood draw during a flare. Also request a baseline tryptase drawn when you are symptom-free. Comparing the two values is essential for interpretation.

24-hour urinary metabolite testing

Urine tests have an advantage over serum tryptase: they capture mediator release over a 24-hour period rather than a single point in time. This makes them more likely to detect episodic mast cell activation, particularly in patients whose flares are frequent but unpredictable. The key urinary tests for MCAS evaluation include 24-hour urinary N-methylhistamine, which measures the primary metabolite of histamine, 24-hour urinary prostaglandin D2 or its metabolite 11-beta-prostaglandin F2 alpha, which captures prostaglandin release from mast cells, and 24-hour urinary leukotriene E4, which measures leukotriene production. Each of these mediators may be elevated independently. A patient whose mast cells preferentially release prostaglandins rather than histamine may have normal urinary histamine metabolites but elevated prostaglandin D2 metabolites. For this reason, many MCAS specialists recommend ordering a panel of all three urinary tests rather than relying on any single marker.

Proper urine collection is important. The sample must be refrigerated throughout the 24-hour collection period (some labs require the collection to be kept on ice or with a preservative). Certain foods and medications can interfere with results. NSAIDs, aspirin, and antihistamines should be discussed with your ordering physician before the collection, as they may need to be held temporarily. Following the lab's specific instructions is essential for accurate results.

The H1/H2 antihistamine trial

One of the most practical diagnostic tools for MCAS is a therapeutic trial of combined H1 and H2 antihistamines. This approach provides both diagnostic information and potential symptom relief. The standard trial involves a second-generation H1 antihistamine (cetirizine 10 mg daily, fexofenadine 180 mg daily, or loratadine 10 mg daily) combined with an H2 antihistamine (famotidine 20 mg twice daily). H1 receptors mediate skin flushing, itching, and some cardiovascular effects. H2 receptors are heavily expressed in the GI tract and mediate gastric acid secretion and intestinal motility effects.

The trial should run for at least 2-4 weeks at consistent doses before assessing response. Some patients notice improvement within days; others require the full trial period. Significant improvement in both GI and non-GI symptoms supports mast cell involvement and meets one of the Valent diagnostic criteria (response to mast cell-targeted therapy). Lack of improvement does not rule out MCAS definitively, as some patients require additional agents like cromolyn sodium or leukotriene inhibitors to achieve response.

âš ī¸Do not adjust or stop other medications without consulting your doctor. The H1/H2 antihistamine trial should be discussed with and ideally supervised by a physician familiar with MCAS. Over-the-counter availability of these antihistamines does not mean they should be started without medical guidance, particularly if you are taking other medications.

Additional tests your specialist may consider

Beyond the primary mediator tests, an allergist or immunologist evaluating for MCAS may order additional studies depending on clinical context.

  • Serum chromogranin A, a neuroendocrine marker that can be elevated in MCAS but is also affected by PPI use and other conditions. Results must be interpreted carefully.
  • Serum heparin levels during a symptomatic episode, as heparin is released by activated mast cells. This test is not widely available and is primarily used in research settings.
  • Plasma histamine, which can be measured but has a very short half-life (approximately 1 minute in plasma), making it technically difficult to capture reliably.
  • Bone marrow biopsy may be considered if mastocytosis (abnormal mast cell proliferation rather than activation) is suspected, particularly if baseline tryptase is persistently elevated above 20 ng/mL.
  • KIT D816V mutation testing, typically from bone marrow, differentiates systemic mastocytosis from MCAS. This is not routine for MCAS evaluation unless mastocytosis is specifically suspected.

Finding the right specialist

Allergists and immunologists are the specialists best equipped to diagnose and manage MCAS. However, not all allergists have experience with mast cell disorders. Finding the right one may require some research. Look for allergists or immunologists who specifically list mast cell activation syndrome or mast cell disorders in their clinical focus areas. Academic medical centers with allergy/immunology departments are more likely to have physicians familiar with MCAS evaluation. The Mast Cell Disease Society and The Mastocytosis Society maintain provider directories that can help identify experienced clinicians in your area.

If you cannot find an MCAS-experienced allergist locally, some specialists offer telemedicine consultations for initial evaluation and test ordering, with local labs used for specimen collection. Your gastroenterologist may also be willing to order initial screening tests (serum tryptase, urinary metabolites) before referring you, which can expedite the process.

What helps with tracking symptoms for your specialist

MCAS diagnosis depends heavily on pattern recognition across body systems and over time. Detailed symptom tracking before and during the evaluation process gives your specialist the clinical context needed to interpret test results and make diagnostic decisions. Record all symptoms across body systems (GI, skin, cardiovascular, neurologic, respiratory), their timing, duration, and severity, along with potential triggers including specific foods, environmental exposures, physical activity, temperature changes, and stress. The GLP1Gut app can help organize this data by logging meals, symptoms, and patterns in a format that is easy to share with your doctor. Start logging at least 2-3 weeks before your specialist appointment.

What to expect from the diagnostic process

MCAS diagnosis is rarely straightforward. Expect the process to take weeks to months rather than days. Initial evaluation will involve a thorough clinical history covering all organ systems. Your specialist may order baseline labs (tryptase, CBC with differential, comprehensive metabolic panel) along with standing orders for acute tryptase draws during flares. 24-hour urine collections may be ordered for one or more symptomatic days. An H1/H2 antihistamine trial will likely be initiated. Follow-up appointments will assess response and refine the diagnosis.

Normal initial lab results do not end the evaluation. Because MCAS is episodic, a single round of testing may not capture mediator elevation even if the condition is present. Your specialist may recommend repeating tests during a more severe flare or adding additional mediator measurements. Persistence and good documentation of symptoms are the most important factors in getting an accurate diagnosis.

Frequently Asked Questions

How much does MCAS testing cost?

Serum tryptase costs approximately $50-150 per draw. 24-hour urinary metabolite panels range from $200-600 depending on the lab and number of metabolites tested. Insurance coverage varies. Some insurers cover tryptase readily but may require prior authorization for the urinary panels. Check with your insurance before ordering.

Can my gastroenterologist test me for MCAS?

A gastroenterologist can order serum tryptase and urinary metabolite tests. However, most GI doctors are not trained in MCAS diagnostic interpretation or management. Ideally, testing should be coordinated with an allergist/immunologist who can interpret results in the context of multi-system symptoms and guide treatment if the diagnosis is confirmed.

Should I stop antihistamines before MCAS testing?

This depends on the specific test. Antihistamines do not affect serum tryptase levels and do not need to be stopped for tryptase testing. For urinary histamine metabolites, some labs recommend holding antihistamines for 48-72 hours before collection. Discuss the specific protocol with your ordering physician and the testing laboratory.

What if my tests are normal but I respond to antihistamines?

Response to H1/H2 antihistamines with normal mediator levels is a common clinical scenario. Under the broader MCAS diagnostic criteria (Molderings, Afrin), clinical response to mast cell-targeted therapy is itself a diagnostic criterion. Even under the stricter Valent criteria, a clinical response warrants continued treatment. The lack of lab confirmation may reflect the limitations of current testing rather than the absence of mast cell involvement.

How quickly can I expect results from MCAS testing?

Serum tryptase results typically return within 1-3 business days. 24-hour urinary metabolite panels may take 5-10 business days depending on the lab. The diagnostic timeline is longer than the lab turnaround because multiple rounds of testing, an antihistamine trial, and clinical correlation are usually needed.

âš ī¸This article is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition.

Key Takeaways

  1. 1Serum tryptase must be drawn during or within 1-4 hours of a symptomatic episode and compared to your personal baseline to be diagnostically useful.
  2. 224-hour urine collections for N-methylhistamine and prostaglandin D2 metabolites can capture mediator release that a single blood draw misses.
  3. 3An H1/H2 antihistamine trial (cetirizine plus famotidine) is both diagnostic and therapeutic. Significant improvement supports mast cell involvement.
  4. 4Allergists and immunologists, not gastroenterologists, are the primary specialists for MCAS evaluation.
  5. 5Normal lab results between episodes do not rule out MCAS. The episodic nature of the condition requires testing during flares.

Sources & References

  1. 1.Mast cell activation syndrome: proposed diagnostic criteria - Valent P et al., Journal of Allergy and Clinical Immunology (2012)
  2. 2.Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options - Akin C, Journal of Hematology & Oncology (2017)
  3. 3.Mast cell activation syndrome: a review - Molderings GJ et al., Journal of Hematology & Oncology (2011)
  4. 4.Biology of human tryptase - Schwartz LB, Annals of Allergy, Asthma & Immunology (2006)
  5. 5.The mast cell stabilizer ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome - Klooker TK et al., Gut (2010)
  6. 6.Presentation, diagnosis, and management of mast cell activation syndrome - Afrin LB et al., Current Allergy and Asthma Reports (2020)
  7. 7.Mast Cell Activation Syndrome - American Academy of Allergy, Asthma & Immunology, AAAAI (2024)

Medical Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. Always consult with a qualified healthcare professional before making changes to your diet, medications, or health regimen. GLP1Gut is a tracking tool, not a medical device.

Figure Out What's Actually Triggering You

An AI-powered meal and symptom tracker that connects what you eat to how you feel, built specifically for people on GLP-1 medications experiencing digestive side effects.